This is a commentary on a paper that analyzes the prognosis and time course of improvement for Long COVID based on data from ...
About half of people with long COVID see meaningful improvement in their symptoms after three years, a new study found.
A long-term study reveals that while many patients see symptom improvement over time, targeted clinical trials remain ...
Patients began raising the alarm about what we now know as long COVID way back in 2020. Once science caught up, the quest was ...
Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute ...
A prospective cohort study found that about half of people living with long COVID a year after their initial COVID-19 ...
Paxlovid (nirmatrelvir-ritonavir) does not reduce hospital admissions or deaths in vaccinated adults at higher risk of severe COVID-19, despite helping them recover faster, according to results from ...
BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has ...